Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...
with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback